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Although cancer metabolism has received considerable attention over the past decade, our
knowledge on its specifics is still fragmentary. Altered cellular metabolism is one of the
most important hallmarks of cancer. Cancer cells exhibit aberrant glucose metabolism char-
acterized by aerobic glycolysis, a phenomenon known as Warburg effect. Accelerated glu-
cose uptake and glycolysis are main characteristics of cancer cells that allow them for inten-
sive growth and proliferation. Accumulating evidence suggests that O-GlcNAc transferase
(OGT), an enzyme responsible for modification of proteins with N -acetylglucosamine, may
act as a nutrient sensor that links hexosamine biosynthesis pathway to oncogenic signaling
and regulation of factors involved in glucose and lipid metabolism. Recent studies suggest
that metabolic reprograming in cancer is connected to changes at the epigenetic level.
O-GlcNAcylation seems to play an important role in the regulation of the epigenome in
response to cellular metabolic status.Through histone modifications and assembly of gene
transcription complexes, OGT can impact on expression of genes important for cellular
metabolism.This paper reviews recent findings related to O-GlcNAc-dependent regulation
of signaling pathways, transcription factors, enzymes, and epigenetic changes involved in
metabolic reprograming of cancer.
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CANCER CELL METABOLISM
Most early studies concerning cancer biology focused only on mol-
ecular alterations in signaling pathways that led to uncontrolled
proliferation, while changes in cancer metabolism were treated
as a secondary effect. However, in recent years, a growing body
of evidence has demonstrated that metabolic reprograming can
be a key process during tumorigenesis and many oncogenes and
tumor suppressors are, in fact, regulators of metabolism. Changes
in metabolism are necessary for the shift from normal to malignant
growth (1).
Abbreviations: 4EBP1, factor 4E binding protein 1; α-KG, alpha ketoglutarate;
ACC, acetyl-CoA carboxylase; ACL, ATP citrate lyase; Akt, v-akt murine thymoma
viral oncogene; ALDA, aldolase A; AMPK, 5′ adenosine monophosphate-activated
protein kinase; BADGP, benzyl-2-acetamido-2-deoxy-α-d-galactopyranoside; CAD,
carbamoyl phosphate synthetase aspartate transcarbamylase and dihydroorotase;
CBP, CREB binding protein; ChRE, carbohydrate response element; ChREBP, carbo-
hydrate responsive element-binding protein; eIF4E, eukaryotic translation initiation
factor 4E; ENO1, enolase; ERK, extracellular signal-regulated kinase; ERα, estrogen
receptor α; EZH2, enhancer of zeste homolog 2; F6P, fructose-6-phospate; FADH2,
reduced flavin adenine dinucleotide; FAS, fatty acid synthase; FBP1, fructose-
1,6-bisphosphatase-1; FoxO1, forkhead box protein O1; GAPDH, glyceraldehyde
3-phosphate dehydrogenase; GFAT, glutamine fructose-6-phosphate amidotrans-
ferase; Glc, glucose; GlcNAc, N -acetylglucosamine; GLS, glutaminase; GLUT, glu-
cose transporter; GSK3β, glycogen synthase kinase 3b; H2Bub, monoubiquitinated
H2B; HBP, hexosamine biosynthetic pathway; HDAC1/2, histone deacetylases 1/2;
HIF-1, hypoxia-induced factor 1; HK, hexokinase; HR6A/B, human orthologs of
the S.cerevisiae ubiquitin conjugated enzyme Rad6; IκB, inhibitor of kappa B;
IKK, I kappa B kinase; LDHA, lactate dehydrogenase A; LKB1, liver kinase B1;
L-PK, liver pyruvate kinase; mTOR, mammalian target of rapamycin; mTORC1/2,
mammalian target of rapamycin complex 1/2; NADH, nicotinamide adenine din-
ucleotide; NButGT, 1,2-dideoxy-2′-propyl-alpha-d-glucopyranoso-[2,1-d]-delta
2′-thiazoline; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B
Cancer cell metabolism is characterized by an enhanced uptake
and utilization of glucose (2–6). In normal cells, glucose is catab-
olized to pyruvate. Pyruvate is further converted to acetylo-CoA
and oxidized to carbon dioxide through the mitochondrial tricar-
boxylic acid (TCA) cycle, which generates NADH and FADH2. The
transfer of electrons from NADH and FADH2 to oxygen through
respiratory chain is an energy-efficient process. Together, glycol-
ysis, TCA cycle, and electrons transfer phosphorylation produce
36 ATP molecules per glucose molecule. In cancer cells, oxidative
phosphorylation is inhibited and cells use glycolysis to provide
cells; ODC, ornithine decarboxylase; OGA, O-GlcNAcase, O-GlcNAc hydrolase;
OGT, O-linked N -acetylglucosamine (O-GlcNAc) transferase; OXPHOS, oxidative
phosphorylation; PDK, pyruvate dehydrogenase kinase; PDK1, phosphoinositide-
dependent kinase-1; PEP, phosphoenolpyruvate; PFK, phosphofructokinase; PGK,
phosphoglycerate kinase-1; PGM, phosphoglycerate mutase; PHD2, prolyl hydrox-
ylase domain protein 2; PI3K, phosphatidylinositol 3-kinase; PIP2, phosphatidyli-
nositol 4,5-bisphosphate; PIP3, phosphatidylinositol 3,4,5-trisphosphate; PIK3CA,
gene encoding the p110alpha catalytic subunit of PI3K; PKA, protein kinase A;
PKM2, pyruvate kinase M2; PP2A, protein phosphatase 2A; PPP, pentose phosphate
pathway; PTEN, phosphatase and tensin homolog; PUGNAc, O-(2-acetamido-
2-deoxy-d-glucopyranosylidene)amino-N -phenylcarbamate; Rheb, Ras homolog
enriched in brain; RNF20, ring finger protein 20; S6K, ribosomal protein S6 kinase;
SAGA, Spt-Ada-Gcn5 histone acetyltransferase complex; SCD1, stearoyl-CoA desat-
urase; SHMT, serine hydroxymethyl transferase; SLC2A1, solute carrier family 2
member 1, gene encoding GLUT1; SLC2A3, solute carrier family 2 member 3,
gene encoding GLUT3; SOC2, cytochrome c oxidase 2; TCA, tricarboxylic acid
cycle; TET, ten–eleven translocation methylcytosine dioxygenase; TNF, tumor necro-
sis factor; TPI, triose phosphate isomerase; TSC1/2, tuberous sclerosis complex
1/2; Ubp8, ubiquitin-specific peptidase 8; UDP-GlcNAc, Uridine diphosphate N -
acetylglucosamine; USP22, ubiquitin-specific protease 22; VHL, von Hippel–Lindau
tumor suppressor protein; Xyl-5-P, xylulose-5-phosphate.
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FIGURE 1 | Metabolic differences between normal and cancer cells are
shown. In normal cells, glucose is metabolized to pyruvate, which is
completely oxidized to CO2 through the TCA cycle and the oxidative
phosphorylation process in the mitochondria. Only if O2 is limited, pyruvate
is metabolized to lactate. Cancer cells convert most glucose to lactate
regardless of the availability of O2 (the Warburg effect). Secretion of lactate
favors tumor progression. The increased glucose utilization through
glycolytic pathway generates metabolic intermediates such as
glucose-6-phosphate, which is used for the synthesis of nucleic acids
through the pentose phosphate pathway. Glutamate produced during
glutaminolysis serves as the major substrate to refuel the TCA cycle.
Citrate-derived acetyl CoA is used for lipid production. The increased
synthesis of nucleic acid and lipids promote proliferation and growth of
cancer cells.
them with the necessary energy. Glycolysis can only provide 2
ATP molecules per glucose molecule producing lactic acid as the
end product. Cancer cells preferentially use glycolysis even in
the abundance of oxygen whereas normal cells use only when
oxygen supply is limited (4–6). The increased glucose uptake
with concomitant lactate production, even under aerobic con-
ditions, is known as the Warburg effect or aerobic effect (2, 3)
(Figure 1).
It was originally hypothesized that these metabolic changes in
cancer cells reflected damage to mitochondrial oxidative phospho-
rylation, suggesting that cancer cells are forced to use glycolysis
instead of oxidative phosphorylation (1–3). However, it has been
revealed that many cancer cells are capable of synthesizing ATP
through mitochondrial respiration (7, 8). There is also no strong
evidence that respiration is less active in cancer cells than in
normal cells. Additionally, mitochondria play important role in
cancer because they are involved in biosynthesis of molecules nec-
essary for growth and proliferation. Impairment of mitochondrial
function has been shown to suppress tumor growth (9). There-
fore, increased glycolysis is not just a consequence of impaired
mitochondria but rather constitutes a primary change of cancer
metabolism.
In fact, increased glycolytic flux is very beneficial to cancer cells
because the glycolytic intermediates fuel several biosynthetic path-
ways that produce de novo nucleotides, lipids, amino acids, and
NADPH. Reprograming of cellular metabolism toward synthesis
of precursors for macromolecules allows for the accumulation of
biomass during cell growth and proliferation (10, 11). Moreover,
cancer cells are more resistant to hypoxia condition associated with
tumor growth by switching their metabolism from oxidative phos-
phorylation to oxygen-independent glycolysis (12). By producing
an increased amount of lactic acid, cancer cells can lower the
pH of extracellular microenvironment, which induces the activity
of metalloproteases and facilitates degradation of extracellular
matrix components. Thus, lactate can be an inducer of cancer
invasion and metastasis (13–15) (Figure 1).
The molecular mechanisms that control metabolic reprogram-
ing in cancer cells are complex. Tumors conduct aerobic glycolysis
and upregulate glutaminolysis, lipid metabolism, and pentose
phosphate pathway (PPP), partly through the activation of onco-
genes or loss of tumor suppressor activity. Oncogenes such as Akt
or c-Myc are promoters of cancer metabolic changes. In contrast,
tumor suppressors such as p53 or AMP-activated protein kinase
(AMPK) prevent those alterations (6, 16, 17). It is also suggested
that epigenetic changes may contribute to the Warburg effect (18).
O-GlcNAcylation
O-GlcNAcylation is a post-translational modification of cellular
proteins that is suggested to play a role in the nutrient sensing
mechanism (19, 20). This modification results from the enzy-
matic addition of the N -acetylglucosamine (GlcNAc) moiety to
the hydroxyl groups of serines or threonines. O-GlcNAcylation
is dynamically regulated by O-GlcNAc transferase (OGT) and
O-GlcNAcase (OGA), which are respectively responsible for O-
GlcNAc addition and removal (21, 22). O-GlcNAc modification
level of proteins is dependent on the concentration of UDP-
GlcNAc, which is a donor substrate for OGT. UDP-GlcNAc
is the end product of the hexosamine biosynthetic pathway
(HBP), which directly uses cell glucose input. Consequently, O-
GlcNAcylation is modulated by nutrients availability. Therefore,
O-GlcNAcylation is proposed as a nutrient sensor and meta-
bolic regulator (19, 20, 23). Glucose and glutamine are the two
most abundant extracellular nutrients and cancer cells are highly
dependent on availability of these compounds. Glutamine is
the donor substrate in the conversion of fructose-6-phosphate
to glucosamine-6-phosphate by glutamine:fructose-6-phosphate
amidotransferase (GFAT) in the HBP. Thus, an excess in both
glutamine and glucose uptake in cancer cells contributes to an

























































Józ´wiak et al. O-GlcNAc and cancer metabolism
FIGURE 2 | O-GlcNAc and cancer metabolism. O-GlcNAcylation level of
proteins is dependent on concentration of UDP-N -acetylglucosamine
(UDP-GlcNAc), which is a donor substrate for O-GlcNAc transferase (OGT).
UDP-GlcNAc is derived from glucose through hexosamine biosynthetic
pathway. In this pathway, fructose-6-phospate (F6P) is converted to
glucosamine-6-phosphate by the glutamine:fructose-6-phosphate
amidotransferase (GFAT) and after the subset of reactions UDP-GlcNAc is
generated. OGT modifies and regulates several glycolytic enzymes,
transcription factors as well as components of PI3K/Akt/mTOR pathway. Akt,
c-Myc, ChREBP, NF-kB, and HIF-1α reprogram cellular metabolism by direct or
indirect regulation of expression of glucose transporters (GLUT1, GLUT3,
GLUT4), glycolytic enzymes (HK, PFK, GAPDH, PGK1, ENO1, PKM2, L-PK,
LDHA), pyruvate dehydrogenase kinase (PDK), glutaminase (GLS), cytochrome
c oxidase 2 (SCO2), fatty acid synthase (FAS), ATP citrate lyase (ACL).
increased flux through the HBP. This in turn contributes to an
increased level of the HBP end product, i.e., UDP-GlcNAc and
increased O-GlcNAcylation (19, 20, 23) (Figure 2).
O-GlcNAcylation occurs on serine or threonine residues of pro-
teins at sites that may also be phosphorylated. Therefore, extensive
crosstalk exists between phosphorylation and O-GlcNAcylation.
At first, it was suggested that O-GlcNAcylation is a reciprocal to
phosphorylation and these modifications are mutually exclusive.
However, recent studies have shown that some cellular stimuli are
able to increase both modifications on the same proteins. Thus,
the interplay between O-GlcNAcylation and phosphorylation is
more complex than previously assumed (24).
The results of many studies suggest that increased expression
of OGT and hyper-O-GlcNAcylation are the universal features of
cancers [for review see Ref. (25–27)]. Aberrant O-GlcNAcylation
seems to be involved both in tumorigenesis and cancer pro-
gression. O-GlcNAcylation of oncogenes, tumor suppressors, and
other proteins involved in cell signaling pathways may significantly
impact tumor growth, cell proliferation, angiogenesis, invasion,
and metastasis. A growing body of evidence suggests that hyper-O-
GlcNAcylation may also be an important factor in reprograming
of cancer cell metabolism (Figure 2).
IMPACT OF O-GlcNAcylation ON KEY FACTORS IN CANCER
METABOLISM
PI3K/Akt/mTOR PATHWAY
Phosphatidylinositol 3-kinase/Akt/mTOR signaling pathway is a
key mechanism involved in both growth and glucose metabolism
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control in cells. Constitutively activated PI3K/Akt/mTOR signal-
ing as a consequence of PIK3CA mutations or PTEN loss is one of
the most common lesion in human cancers (28–30).
The activation of phosphatidylinositol 3-kinase (PI3K) leads to
the phosphorylation of phosphatidylinositol 4,5-bisphosphate to
phosphatidylinositol 3,4,5-trisphosphate and subsequent recruit-
ment of Akt to the plasma membrane where this kinase is activated
(31). Akt is partially activated through an initial phosphorylation
at Thr308 by phosphoinositide-dependent kinase-1 (PDK1) and
then fully activated by the phosphorylation at Ser473 by a mam-
malian target of rapamycin complex 2 (mTORC2) (32–36). Akt
can directly or indirectly affect the activity of many transcrip-
tion factors and enzymes mediating multiple effects (35, 36). One
of the major downstream effectors of Akt is the serine/threonine
kinase mTOR. mTOR constitutes catalytic subunit of the function-
ally distinct mTORC1 and mTORC2 complexes. Akt can activate
mTORC1 indirectly through phosphorylation and inhibition of
tuberous sclerosis complex 2 (TSC2) (37) (Figure 3).
Phosphatidylinositol 3-kinase/Akt/mTOR signaling pathway
plays a central role in cancer cell metabolism reprogram-
ing (30). PI3K/Akt pathway regulates glucose uptake and uti-
lization (5). Activation of PI3K/Akt causes increased glucose
transporters expression on the cell surface, activation of
FIGURE 3 | PI3K/Akt/mTOR signaling pathway. mTORC1 is activated by
receptor signaling through the PI3K/Akt pathway. mTORC2 is crucial factor
in PI3K/Akt signaling, phosphorylating Akt on Ser473 to promote its
maximal activation. mTOR regulates protein O-GlcNAcylation through
affecting OGT stability. Several proteins of PI3K/Akt/mTOR pathway are
modified by OGT, i.e., PI3K, PDK1, and Akt.
hexokinase (HK) that phosphorylates glucose to keep it in cell
and phosphofructokinase-2-dependent allosteric activation of
phosphofructokinase-1 (PFK1), which catalyzes the committed
step of glycolysis (1). Moreover, activation of PI3K/Akt/mTOR
pathway enhances the biosynthesis of macromolecules. PI3K and
Akt stimulate expression of lipogenic genes and lipid synthesis
in many cell types, while mTOR regulates protein translation
(38–40).
The role of O-GlcNAcylation in regulation of PI3K/Akt sig-
naling pathway was extensively studied especially in adipocytes
and muscle cells (41–45). It was shown that overexpression of
OGT and increased O-GlcNAcylation in muscle, adipocytes, or
liver cells inhibited insulin signaling (23, 43, 46, 47). How-
ever, studies using OGA inhibitors gave contradictory results.
Inhibition of OGA by PUGNAc [O-(2-acetamido-2-deoxy-d-
glucopyranosylidene)amino-N -phenylcarbamate] increased global
O-GlcNAc levels and caused insulin resistance in 3T3-L1
adipocytes and skeletal muscle (40, 43). But the other studies
showed that more selective than PUGNAc inhibitor NButGT
(1,2-dideoxy-2′-propyl-alpha-d-glucopyranoso-[2,1-d]-Delta 2′-
thiazoline) did not induce insulin resistance in 3T3-L1 adipocytes
(48, 49).
Akt is one of the most frequently investigated O-GlcNAcylated
proteins. In murine pancreatic β-cells, Akt1 Ser473 may undergo
both phosphorylation and O-GlcNAcylation and the balance
between these modifications may regulate cell apoptosis (50).
However, the relationship between O-GlcNAcylation and phos-
phorylation of Akt in cancer cells is not fully elucidated. Wang
et al. showed that O-GlcNAcylations at Thr305 and Thr312 inhib-
ited Akt phosphorylation at Thr308 via disrupting the interac-
tion between Akt and PDK1 in MCF-7 cells (51). The impaired
Akt activation affected functions of Akt, as evidenced by sup-
pressed cell proliferation and migration capabilities. On the other
hand, Kanwal et al. showed that in MCF-7 cells treated with
PUGNAc and glucosamine the phosphorylation of Akt Ser473
was higher (52). Similarly, in thyroid anaplastic cancer cells,
down-regulation of OGA and increased O-GlcNAcylation caused
increased Akt1 Ser473 phosphorylation and enhanced prolifera-
tion (53). Onodera et al. found that OGT inhibition by BADGP
(benzyl-2-acetamido-2-deoxy-α-d-galactopyranoside) or down-
regulation by siRNA led to suppression of Akt signaling in 3D
cultures of breast cancer cells (54).
Additionally, PI3K/Akt pathway is sensitive to extracellular
glucose. Jones et al. have shown that short-term glucose depri-
vation significantly restricts insulin-stimulated Akt activation and
inhibits growth of U2OS cancer cells (55). The authors found
that insulin signaling can be rescued by extracellular glucosamine
and increased flux through the HBP and O-GlcNAcylation
(55). Together, these data seem to support the concept that in
cancer cell metabolism, reprograming increased HBP flux and
O-GlcNAcylation may play an important role.
Recent studies have also shown that mTOR regulates protein
O-GlcNAc modification through affecting OGT stability. Inhibi-
tion of mTOR causes a decrease in global O-GlcNAcylation due
to decreased OGT protein level (56).
Thus, many studies have pointed to O-GlcNAcylation as a key
regulatory modification of PI3K/Akt/mTOR pathway. But further
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studies are necessary to provide direct evidence for the role of O-
GlcNAcylation in PI3K/Akt/mTOR pathway in cancer metabolism
regulation.
HYPOXIA-INDUCED FACTOR
Hypoxia is an important characteristic of the tumor microenvi-
ronment (57–59). Decreased oxygen availability stimulates cells
to consume more glucose and produce lactate (59). This adap-
tive response to reduced O2 availability is mediated by hypoxia-
induced factors 1 and 2 (HIF-1 and HIF-2). These factors are com-
posed of the constitutively expressed HIF-1β subunit and either
the HIF-1α or HIF-2α subunit, which are stable only in hypoxia
conditions (17, 58). HIF-1α is ubiquitously expressed whereas
HIF-2α expression is restricted to several cell types. Under nor-
moxic conditions, the HIF-1α subunit undergoes hydroxylation
on Pro402 and/or Pro564 by prolyl hydroxylase domain protein 2
(PHD2), which uses O2 and α-ketoglutarate (α-KG) as substrates
(58). Hydroxylated HIF-1α is recognized by von Hippel–Lindau
(VHL) tumor suppressor protein, which recruits an E3-ubiquitin
ligase that targets HIF-1α for proteasomal degradation. Under
hypoxic conditions, the prolyl hydroxylation reactions are inhib-
ited by O2 deprivation and HIF-1α accumulates and dimerizes
with constitutively expressed HIF-1β. HIF-1 dimer binds to the
hypoxia response element of target genes and causes their tran-
scriptional activation. HIF-1’s targets include SLC2A1 and SLC2A3
genes encoding for glucose transporters (GLUT1 and 3, respec-
tively) as well as genes encoding for most of glycolytic enzymes
(58) (Figure 4).
Recent studies revealed that O-GlcNAcylation may affect cancer
metabolism reprograming by regulation of HIF-1 pathway (60).
In human breast cancer cells, high level of HIF-α is associated
with elevated OGT level. Ferrer et al. showed that reduction of O-
GlcNAcylation in cells increased HIF-1α hydroxylation and inter-
action with VHL resulting in HIF-1α degradation and reduction
of GLUT1 expression (60).
c-Myc
c-Myc is a helix–loop–helix leucine zipper transcription fac-
tor, which participates in many cellular processes including cell
proliferation, apoptosis, and differentiation (61, 62). This tran-
scription factor is also a key regulator of cancer cell metabo-
lism. In transformed cells, c-Myc is often expressed at constitu-
tively high levels and promotes energy production and biomol-
ecule synthesis independent of growth factor stimulation (16).
Activated c-Myc induces the expression of almost all glycolytic
enzymes, particularly hexokinase 2 (HK2), phosphofructokinase-
1 (PFK1), phosphoglycerate kinase-1 (PGK1), lactate dehydro-
genase A (LDHA), and pyruvate kinase M2 (PKM2) (17, 63).
c-Myc not only promotes energy production by enhancing gly-
colysis but also increases biomolecule synthesis by targeting genes
of anabolic enzymes such as carbamoyl phosphate synthetase
aspartate transcarbamylase and dihydroorotase (CAD), serine
hydroxymethyl transferase (SHMT), fatty acid synthase (FAS), and
ornithine decarboxylase (ODC) (17). Moreover, multiple studies
have demonstrated that c-Myc stimulates glutamine uptake and
metabolism. c-Myc directly stimulates expression of glutamine
FIGURE 4 | Hypoxia-inducible factor regulation is shown. Under normal
condition, HIF-1α subunit hydroxylated by PDH2 can bind to VHL protein,
which promotes the polyubiquitination of HIF-1α and its degradation. The lack
of oxygen prevents the hydroxylation of HIF-1α, leading to its stabilization.
HIF-1α can associate with HIF-1β and the cofactor p300/CBP. The HIF-1
complex induces the transcription of genes containing hypoxia-responsive
elements (HRE). OGT regulates stability of HIF-1α via regulation of
α-ketoglutarate levels and inhibiting HIF-1α hydroxylation.
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FIGURE 5 | c-Myc stability regulation. ERK phosphorylates c-Myc on Ser62,
resulting in stabilization of protein. Phosphorylated on Ser62 c-Myc can be
modified by GSK3β on Ser58. PP2A can dephosphorylate Ser62. Thr58
mono-phosphorylated c-Myc is a target for ubiquitin ligase complex, leading
to proteasomal degradation. O-GlcNAcylation of Thr58 can compete with
phosphorylation and potentially increase stability of c-Myc.
transporters and indirectly promotes glutaminase (GLS) activ-
ity by repressing expression of miR-23a/b, which targets GLS1
transcript (64–66). High level of c-Myc in cancer cells causes glu-
tamine addiction, and cells undergo apoptosis when deprived of
glutamine (64).
Stability of c-Myc is controlled by phosphorylation of spe-
cific sites (67, 68). Activated extracellular receptor kinase (ERK)
stabilizes c-Myc by phosphorylation at Ser62. Once c-Myc phos-
phorylated at Ser62, it is recognized by GSK3β, which phospho-
rylates it at Thr58. At that time, dephosphorylation of Ser62 is
mediated by protein phosphatase 2A (PP2A) (69). c-Myc phos-
phorylated at Thr58, but not at Ser62 is recognized by the E3 ligase,
which ubiquitinates c-Myc at the N-terminus and targets it for
proteasome-dependent degradation (69, 70). Thus, phosphoryla-
tion of Thr58 is a key event in c-Myc regulation (Figure 5). Muta-
tion of Thr58 has been observed in Burkitt’s lymphomas and is
associated with increased c-Myc protein stability. It was shown that
c-Myc could be also O-GlcNAcylated at Thr58 (71–73). Increased
Thr58 O-GlcNAcylation could compete with phosphorylation and
potentially stabilize c-Myc. Moreover, PP2A has been found to be
O-GlcNAcylated in oocytes of Xenopus laevis (74). However, the
significance of its O-GlcNAcylation in cancer cells has not been
established. Recently, Itkonen et al. have shown that OGT is, in
fact, a central regulator of c-Myc stability in prostate cancer cells
(75). OGT inhibition elicited a dose-dependent decrease in the
levels of c-Myc protein but not c-Myc mRNA in prostate cell lines
(75). Collectively, these data suggest that OGT by modification
of c-Myc and PP2A could potentially regulate c-Myc stability and
affect its function in cancer cell metabolism.
NF-κB
NF-κB is a glucose-responsive transcription factor that is involved
in many biological processes such as inflammation and immune
response, cell survival, growth, and development (76). Five
members of NF-κB transcription factors family have been identi-
fied: p65 (RelA), RelB, c-Rel, p105/p50, and p100/p52. Activation
of NF-κB proteins is tightly regulated and altered activation of
the NF-κB signaling pathways has been linked to autoimmunity,
chronic inflammation, and various cancers. In basal state, NF-
κB is sequestered by inhibitor of κB (IκB) in the cytosol. Upon
stimulation, IκB is phosphorylated by the IκB kinase (IKK) com-
plex and is then degraded by the ubiquitin–proteasome system.
The freed NF-κB translocates into the nucleus and induces gene
transcription (76, 77) (Figure 6).
It has been suggested that NF-κB may be an important factor
promoting the switch of cellular glucose metabolism from oxida-
tive phosphorylation to oxygen-independent glycolysis in tumor
cells (18). Kawauchi et al. showed the link between p53, NF-κB,
and glycolysis (78). In p53-deficient cells, the activity of NF-κB was
found to be enhanced and that caused an increase in the rate of
aerobic glycolysis via upregulation of glucose transporter GLUT3
(78). On the other hand, it was found that NF-κB as a regulator
of mitochondrial respiration, suppressed reprograming to aerobic
glycolysis and prevented necrosis in cells upon nutrient starva-
tion. But this function of NF-κB was p53-dependent and involved
upregulation of mitochondrial synthesis of cytochrome c oxidase
2, which increased oxidative phosphorylation and reduced gly-
colytic flux in cells (79, 80). NF-κB is also involved in metabolism
via p53-independent mechanisms. Kumar et al. have found that
transglutaminase-2 regulates metabolic reprograming in mam-
mary epithelial cells by constitutively activating nuclear factor
NF-κB, which binds to hypoxia-inducible factor promoter and
induces its transcription even under normoxic conditions (81).
Activation of NF-κB requires post-translational modifications
such as phosphorylation and acetylation. Growing evidence also
suggests a pivotal role for O-GlcNAcylation in the activation of
NF-κB (82–86) (Figure 6). The O-GlcNAc modification sites
within NF-κB p65 have been identified as Thr322 and Thr352.
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FIGURE 6 | NF-κB activation is shown. Inactive NF-κB is located in the
cytosol complexed with the inhibitory protein IκB. Activated by extracellular
signals IκB kinase (IKK) phosphorylates the IκB protein, which results in
dissociation of IκB from NF-κB, ubiquitination, and degradation of IκB by the
proteosome. The activated NF-κB is then translocated into the nucleus where
it binds to specific sequences of DNA. O-GlcNAcylation favors activation of
NF-κB by regulation of IKKβ activity, inhibition of the interaction of NF-κB with
IkB, and promotion of NF-κB acetylation.
O-GlcNAc modification of NF-κB p65 at Thr352 in response to
high glucose has been shown to inhibit the interaction of NF-κB
with IκB, causing the nuclear translocation of NF-κB and activa-
tion of its target genes (83). Recently, Allison et al. have demon-
strated that OGT localizes to chromatin and drives p300-mediated
acetylation of p65 at Lys310 in response to tumor necrosis factor
(TNF) (84). The studies revealed that Thr305 was an important
residue required for an attachment of the O-GlcNAc moiety on
p65. The attachment of the O-GlcNAc moiety to p65 at Thr305 is
a precondition for Lys310 acetylation, which is necessary for full
NF-κB-dependent transcription (84).
IκB kinase is also O-GlcNAcylated. Kawauchi et al. showed
that loss of p53 enhanced catalytic activity of IKKβ through
O-GlcNAcylation in mouse embryonic fibroblasts (MEFs) and
transformed human fibroblasts (87). O-GlcNAcylation of IKKβ
occurred at Ser733 in the C-terminal domain, which was identified
as an inactivating phosphorylation site. Thus, O-GlcNAcylation of
IKKβ regulates its catalytic activity (87) (Figure 6).
The direct link between HBP, OGT, and NF-κB was shown
in human pancreatic ductal adenocarcinoma cells (PDAC) (85).
Ma et al. have observed increased HBP flux and hyper-O-
GlcNAcylation in PDAC cells, which was associated with increased
OGT and decreased OGA levels (85). In these cells, the NF-
κB p65 subunit and upstream kinases IKKα/IKKβ were O-
GlcNAcylated. Reducing p65 O-GlcNAcylation specifically by
mutating two p65 O-GlcNAc sites caused the reduction of PDAC
cells anchorage-independent growth (85).
p65 is not the only O-GlcNAcylated NF-κB family member.
Ramakrishnan et al. examined the O-GlcNAcylation status of
all of the NF-κβ family proteins in lymphocytes under hyper-
glycemic conditions (86). They have shown that c-Rel is the
major O-GlcNAcylated NF-κβ subunit in lymphocytes, and that
enhancement of its O-GlcNAcylation increases its transcrip-
tional activity. They have identified Ser350 as the site of O-
GlcNAcylation. Mutation of Ser350 blocked the O-GlcNAcylation
of c-Rel and greatly reduced DNA-binding ability and transacti-
vation potential in cells in response to stimulation of the T cell
receptor (86).
CARBOHYDRATE RESPONSIVE ELEMENT-BINDING PROTEIN
Carbohydrate responsive element-binding protein (ChREBP) is
helix–loop–helix leucine zipper transcription factor, which medi-
ates glucose-dependent induction of glycolytic and lipogenic
enzyme genes (88–94). ChREBP is involved in the induction of
liver pyruvate kinase (L-PK) and acting synergistically with sterol
regulatory element-binding protein 1c (SERBP-1c) activates genes
encoding lipogenic enzymes: acetyl-CoA carboxylase (ACC) and
FAS (88–94). ChREBP is expressed in most tissues but the highest
level of this protein is observed in liver and adipocytes (94). The
function of ChREBP in hepatocytes has been extensively studied
but its role in cancer cell metabolism has not been fully eluci-
dated. However, the studies of Tong et al. suggest that ChREBP
plays a key role in regulation of proliferating cells metabolism
(95). This study demonstrated that induction of ChREBP in
response to mitogenic stimulation was required for proliferation of
HCT116 colorectal cancer cells and HepG2 hepatoblastoma cells.
Suppression of ChREBP causes a reduction of aerobic glycolysis,
de novo lipogenesis, and nucleotide biosynthesis but stimulated
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mitochondrial respiration (95). Thus, ChREBP seems to con-
tribute to the glycolytic phenotype exhibited by cancer cells. It
plays a key role in directing glucose metabolism into anabolic
pathways, i.e., lipid and nucleotide biosynthesis during cell growth
(95).
Carbohydrate responsive element-binding protein contains
several phosphorylation sites recognized by protein kinase A
(PKA) such as Ser196, Ser626, and Thr666 that are involved in
negative regulation of its nuclear import and DNA-binding activ-
ity (94). However, mutations of Ser196, Ser626, and Thr666 did
not significantly affect the glucose-responsiveness of ChREBP. It
appears that PKA-mediated phosphorylation and glucose activa-
tion are independent regulatory mechanisms (94).
Carbohydrate responsive element-binding protein is mod-
ified by O-GlcNAcylation and this modification increases its
protein level and transcriptional activity (96, 97) (Figure 7).
O-GlcNAcylation affects ChREBP protein stability and protects
it against proteasomal degradation. O-GlcNAcylated ChREBP
under hyperglycemic conditions shows increased activity toward
its target glycolytic (LPK ) and lipogenic (ACC, FAS, SCD1)
genes (97).
Ido-Kitamura et al. have shown that FoxO1 is a negative regu-
lator of ChREBP activity (98) (Figure 7). FoxO1 decreases glucose
utilization and lipid synthesis by reducing ChREBP activity. Over-
expression of FoxO1 in hepatocytes attenuated ChREBP activity
by suppressing O-GlcNAcylation and reducing the protein stabil-
ity. FoxO1 inhibits high glucose- or OGT-induced L-PK promoter
FIGURE 7 | ChREBP activation is shown. ChREBP is phosphorylated by
PKA. Dephosphorylation of Ser196 and Thr666 ChREBP is required for its
translocation into the nucleus and DNA binding. A particular isoform of
protein phosphatase 2A (PP2A), selectively activated by Xyl-5-P, an
intermediate of pentose phosphate pathway, is responsible for both
cytosolic and nuclear dephosphorylation of ChREBP. O-GlcNAcylation of
ChREBP increases its protein level and transcriptional activity.
Overexpression of FoxO1 attenuates ChREBP activity.
activity by decreasing ChREBP recruitment to the L-PK promoter
(98). However, the exact mechanism by which FoxO1 inhibits
ChREBP O-GlcNAcylation is not known.
GLYCOLYTIC ENZYMES
Several glycolytic enzymes related to Warburg effect are O-
GlcNAcylated (99–101). One of the most important enzymes
involved in cancer cell metabolism reprograming is pyruvate
kinase (PK) (17). This enzyme catalyzes a reaction generating
pyruvate and ATP from phosphoenolpyruvate (PEP) and ADP
(102). There are four isozymes of PK (L, R, M1, and M2) and
these vary in tissue distribution, kinetic characteristics, and reg-
ulatory mechanism. PKL and PKR are products of PKL gene,
transcribed with different promoters (103). PKM1 and PKM2 are
encoded by the PKM gene and are the products of two alternatively
spliced exons (exon 9 and exon 10, respectively) (104). Isozyme
M1 is expressed in most adult differentiated tissues, whereas M2
is expressed in embryonic cells, adult stem cells, and cancer cells
(105). PKM2 possesses unique properties important in the repro-
graming of cell metabolism. Active PKs consist of four subunits,
and PKL, PKR, and PKM1 form stable tetramers. PKM2 can exist
as an active tetramers and much less active dimers (102). When
PKM2 is in dimeric form, glycolytic intermediates above PK accu-
mulate and may be directed toward anabolic pathways for synthesis
of amino acids, nucleic acids, and phospholipids (17).
O-GlcNAcylation may be involved in regulation of PKM2
activity. The site of O-GlcNAcylation on PKM2 has not been
established. However, the increased O-GlcNAcylation in cells is
associated with a decrease in general PK activity. It is suggested
that hyper-O-GlcNAcylation in cancer cells would likely decrease
PKM2 activity contributing to directing glycolytic intermedi-
ates toward biosynthetic pathways (25). Interestingly, Champat-
tanachai et al. showed that PKM2 is O-GlcNAc modified only in
breast cancer tissues but not in normal samples (101).
To form the active tetramer, PKM2 requires fructose-1,6-
bisphosphate, which is produced in reaction catalyzed by
phosphofructokinase-1 (17).Yi et al. have demonstrated that PFK1
is O-GlcNAcylated at Ser529 in response to hypoxia in cancer cells
(100). Glycosylation inhibits PFK1 activity and redirect the flux of
glucose from glycolysis through the PPP (100). Yi et al. have also
examined the impact of OGT overexpression on HK, PGK, and
PK activities (100). Direct O-GlcNAcylation status of these pro-
teins has not been studied but in cancer cells with increased OGT
activity, HK activity was increased while PGK and PK activities
were decreased (100).
EPIGENETICS, O-GlcNAcylation, AND CANCERMETABOLISM
The connection between cancer metabolism reprograming and
epigenetics may be considered in two aspects. Changes in can-
cer cell metabolism may impact epigenetic gene regulation since
the enzymes involved in modification of histones or chromatin
remodeling utilize substrates generated by metabolic pathways
(106, 107). On the other hand, through modification and remod-
eling of chromatin, extracellular signals from tumor microen-
vironment or nutrition compounds can regulate the expression
of genes involved in cellular proliferation as well as cellular
metabolism (18).
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The studies of Gao et al. have revealed that high glucose is an
inducer of monoubiquitination of histone H2B at Lys120 in cul-
tured glioma cells (108). Nutrient deprivation causes decrease of
H2B ubiquitination (109). Compared to the other histone modi-
fications, ubiquitination is less well studied and its specific roles in
tumors remain to be clarified. However, de-regulation of H2Bub
has been suggested as an etiology factor of cancer development
(110, 111). The enzymes responsible for H2B monoubiquitina-
tion were first identified in Saccharomyces cerevisiae as Rad6 (E2)
and Bre1 (E3). In humans, there are two homologs of Rad6
(HR6A and HR6B) and Bre1 (RNF20 and RNF40) (110). The
latest seem to play main role in ubiquitination of H2B in humans
(112, 113). RNF20 physically interacts with the tumor suppres-
sor protein p53, functioning as a transcriptional co-activator of
p53 (112). RNF20 is also required for p53 expression and RNF20
depletion leads to more than 10-fold decrease in expression of
p53 (114). Monoubiquitination of histone H2B can be reversed
by Ubp8, a component of the transcriptional activator SAGA in
yeast. USP22 is the human homolog of this protein (110). The
results showed also that USP22 is a positive regulator of c-Myc-
dependent transcription and induction of c-Myc targeted genes
is impaired in USP22-depleted cells (115). Although most data
indicate that H2Bub and its ubiquitin ligases act as tumor sup-
pressors, a few studies suggest that their activity may promote
tumorigenesis (116–118). The discrepancies found may be due to
different role of H2B ubiquitination in tumorigenesis and tumor
progression. H2B ubiqiutination may be involved in arising of
tumors and proliferation of cancer cells but may suppress can-
cer stem cell phenotypes. In fact, it has been found that RNF20
and RNF40 knockdown decrease cell proliferation but increase
cell migration (111).
Recent studies have also shown that O-GlcNAcylation plays an
important role in H2B ubiquitination. H2B is O-GlcNAcylated by
OGT at Ser112 (119–122). H2B Ser112 O-GlcNAcylation changes
in response to extracellular glucose (120). It is suggested that H2B
Ser112 O-GlcNAcylation promotes Lys120 monoubiquitination
because GlcNAc moiety can serve as an anchor for a histone
H2B ubiquitin ligase (122). O-GlcNAcylation of H2B is prob-
ably important for transcriptional activation since modified by
O-GlcNAc H2B is frequently located near transcribed genes (120).
H2B Ser112 O-GlcNAcylation depends on TET2/3 (ten-eleven
translocation), which is an enzyme that catalyzes the conversion of
5-methylcytosine to 5-hydoxymethylcytosine (121). TET2 and 3
directly interact with OGT (121, 122). TET2 promotes OGT activ-
ity and facilitates OGT-dependent histone modification (121). Xu
et al. have found that AMPK could suppress histone H2B O-
GlcNAcylation (123). AMPK directly phosphorylates OGT and
this modification inhibits OGT–chromatin association, histones
O-GlcNAcylation, and gene transcription. The authors have sug-
gested that there is a crosstalk between the LKB1-AMPK and the
hexosamine biosynthesis (HBP)-OGT pathways, which coordinate
together for the sensing of nutrient state and regulation of gene
transcription (123).
Additionally, it has been recently found that methyltransferase
EZH2, which is a component of Polycomb repressive complex 2, is
O-GlcNAcylated at Ser75 in breast cancer cells (124). This modifi-
cation stabilizes EZH2 and facilitates the trimethylation of histone
H3 at Lys27. Thus, the study of Chu et al. uncovered a unique
epigenetic role of OGT in regulating histone methylation (124). It
is also possible that OGT by regulation of EZH2 may be involved
in metabolic reprograming. Polycomb group protein EZH2 is a
direct upstream regulator of c-Myc oncogene (125). c-Myc is one
of the main regulators of cancer cell reprograming process. EZH2
was found to activate c-Myc in breast cancer cells through the ERα
and the Wnt pathways (126).
O-GlcNAcylation plays an important role in activation of
NF-κB and this factor seems to be also involved in epigenetic
regulation of Warburg effect. Liu et al. have shown that fructose-
1,6-bisphosphatase-1 (FBP1), which is gluconeogenesis regulatory
enzyme and functions to antagonize glycolysis has been down-
regulated through NF-κB pathway in Ras-transformed NIH3T3
cells (127). The authors have found that inhibition of NF-κB
restored FBP1 expression, partially through demethylation of
FBP1 promoter. NF-kB can be involved in negative regulation
of gene expression through interaction with transcription co-
repressors such as histone deacetylase HDAC1 and HDAC2 (128,
129). Interestingly, HDAC1 has been found to be O-GlcNAcylated
in HepG2 liver carcinoma cells (130). It is suggested that OGT can
contribute along with HDAC to the repression of genes. Moreover,
histone deacetylases can interact with DNA methyltransferases
that by methylation of promoters can cause stable silencing of
gene expression (18).
CONCLUSION
There is no doubt that metabolic reprograming is one of the main
hallmarks of cancer cells. The most important changes in can-
cer metabolism include elevation of glucose uptake and glycolysis,
enhanced glutaminolysis, induction of PPP, and upregulation of
macromolecule synthesis. These changes are beneficial for cancer
proliferation, growth, metastasis, and angiogenesis. Many stud-
ies have shown that O-GlcNAcylation, which acts as a nutrient
sensor, is elevated in different cancers and seems to be respon-
sible for coupling cell metabolic status to signal transduction
and transcription. It is strongly suggested that increased glucose
flux through HBP and elevated UDP-GlcNAc is a general fea-
ture of cancer cells that contributes to hyper-O-GlcNAcylation.
High activity of OGT as a result of both high substrate level
and gene overexpression favors modification of several key factors
involved in cancer metabolism reprograming. O-GlcNAcylation
impacts their stability, activity, localization, interaction with other
proteins, and in consequence, enhances their effect on reprogram-
ing of cell metabolism. Akt, c-Myc, ChREBP, NF-κB, and HIF-1
affect metabolism by direct or indirect regulation of expression
of glucose transporters as well as glutaminolytic, glycolytic, and
lipogenic enzymes. OGT and O-GlcNAcylation may also consti-
tute a link between nutrient status and epigenetic regulation of
gene expression. In response to nutrient availability, OGT may
directly affect histone code by attachment of N -acetylglucosamine
residues. Moreover, OGT can indirectly influence gene expression
by interactions with histone modifying enzymes and modulation
of their stability and activity. However, although a large body of
evidence has demonstrated the significance of O-GlcNAcylation
in metabolism regulation, there is still much to learn about its role
in cancer metabolism reprograming. Elucidating the relationship
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between O-GlcNAc cycling controlling mechanism and cellular
metabolic activity of cancer cells is an exciting challenge for future
research.
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